Manuscript Preparation

• Full-length manuscript
• Brief Report
• Reviews
• Minireviews
• Technical and Case report

Copyright Transfer
Archiving in PMC/UKPMC
Manuscript Preparation
Peer Review Information
Reviewers
Editorial Policies
Reprints
Immune Network Editorial Board
Submit Online

------------------------------------------------------------------------------------------------------
Copyright Transfer

All manuscripts are considered to be the property of KAI from the time of submission. Should KAI not publish the paper, KAI releases its rights therein at the time the manuscript is returned to the corresponding author.

Manuscripts published in Immune Network become the sole property of, with all rights in copyright reserved to, The Korean Association of Immunobiologists, Inc. (KAI).

The corresponding author, on behalf of all authors, signs a copyright transfer form. Authors of articles written as part of their official duties as employees of the Korean government are exempt from this requirement for transfer of copyright.

Authors retain the following permissions as long as proper attribution (Originally published in Immune Network. Author(s). Year. Title. Immune Network. Vol: pp-pp. Copyright © [year] The Korean Association of Immunobiologists, Inc.) is included:

1. If mandated by the funder of the research, authors may deposit the accepted, uncopyedited version of the manuscript into PubMed Central, with an embargo period (time at which the manuscript is available to the public) of 12 months after publication. This right applies solely to deposition into PubMed Central; the authors agree not to deposit the manuscript to any other repository (except a thesis repository if required - see item 3), agency, or entity. Authors whose funder mandates a PubMed Central embargo of 6 months have permission to make the manuscript available at 6 months after publication. This right applies only to articles under a funder mandate to submit to PubMed Central (for research funded by NIH, this means articles accepted for publication on or after April 7, 2008).
2. To reuse original figures or tables in the author's own work. This permission extends to the author only, not to the institution. The author may not permit others to reproduce their figures or tables in works not written by the author.
3. To include the final, published version of the article in a thesis and/or dissertation in print. If required by the degree-conferring institution, an electronic version of the final, published version may be deposited into a thesis repository as long as a link to the article on Immune Network website is included.
4. To reprint the article in print collections composed solely of the author's own writings. Permission must be obtained from KAI to reprint the article in any publication that includes the work of others.
5. To post a copy of the accepted, uncopyedited version on the author's personal website with a notice that "This is the accepted, uncopyedited version of the manuscript. The definitive version was published in Immune Network Vol: pp-pp. DOI." A hyperlink to the published article on Immune Network website must be included; the published PDF may not be displayed. For posting on any other website, including any social media, corporate or government (other than PubMed Central according to the terms in item 1 above) website, permission must be requested from KAI. POSTING TO INSTITUTIONAL REPOSITORIES IS NOT PERMITTED.
6. To present the work orally in part or in its entirety.
7. If the work was prepared as a work-for-hire, the author's employer may print out PDFs or make photocopies for internal use only. Distribution of the article by the author's employer in other formats or for any other purpose requires permission from KAI.

Authors reusing their own material as described in items 1-7 do not need to contact KAI for permission, except where noted. For all other reuse, the authors should contact KAI.

---------------------------------------------------------------------------------------------------------------
Archiving in PMC/UKPMC (see also NIH Public Access Policy and FAQ)

In February 2009, The Korean Association of Immunobiologists (KAI) began a new, free service to authors, to deposit selected manuscripts to PubMed Central (PMC).

How this service works:

• As part of the online submission process, authors select whether or not this service applies to them
• If the manuscript is accepted for publication, KAI will send all files, including Supplemental Data and video files, to NIHMS for display in PMC
• Authors will receive an email from PMC (NIH/NLM/NCBI) to approve the submitted files
• Authors will receive an email from PMC (NIH/NLM/NCBI) to approve the XML format
• After final approval by the author, PMC will make the manuscript publically available after the embargo Period

-------------------------------------------------------------------------------------------------------------------------
Manuscript Preparation

• General Guidelines
• Abbreviations
• Contact Immune Network
• Cover Art
• Depositing in Public Databases
• Estimating Manuscript Length
• Figures
• Figure Legends
• Human and Animal Use
• Keywords
• References
• Style Guide
• Submission Form; Color and/or Supplemental Data Charges Form
• Supplemental Data
• Tables
• Web Links in Manuscripts

General Guidelines
A 12-point serif font, preferably Times New Roman, is required.
Do not use compressed type format.
Double-space entire manuscript.
Prepare the manuscript in the order of Title, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, Conflict of Interest, References, Tables, Figure Legends, Figures, and Supplemental Data.
Each of the section components should begin on a separate page.

Full length Manuscript
1.The Title Page must include

• the full title
• a running title (not to exceed 60 characters)
• each author's full name as it should be published (first name, middle initial, last name)
• the affiliations of all authors and their institutions, departments, or organizations (use the superscript Arabic numbers to designate authors' affiliations)
• List the phone number, fax number, and e-mail address of the corresponding author with separate number on the title page.
• Key words up to 6.
• Abbreviations : Nonstandard abbreviations used three or more times must be defined on the title page.
• See the Submit Online section for information about the corresponding author designation during submission and peer review

2. The Abstract must be 250 words or less for Full-Length type manuscripts. Reference citations should not be included in the Abstract. The species of animals or species of origin of cells used in the manuscript must be clearly stated in the Abstract.
3. The Introduction, Materials and Methods, Results, and Discussion sections should begin on separate pages in that order.
4. Acknowledgments appear immediately after the Discussion and before References. Grant support must be included in the Acknowledgments
5. Conflict of interest. Immune Networks requires all authors to disclose any financial conflict of interest that might be construed to influence the results or interpretation of their manuscript. Authors must declare any such conflict in the cover letter accompanying the manuscript and after the Acknowledgments section of the manuscript itself. The corresponding author will be asked to sign a form on behalf of all the authors regarding potential conflicts of interest at the time of acceptance. As a guideline, any affiliation associated with a payment or financial benefit exceeding $10,000 p.a. or 5% ownership of a company or research funding by a company with related interests would constitute a conflict that must be declared. This policy applies to all submitted research manuscripts and review material.  Examples of statement language include: AUTHOR is an employee and shareholder of COMPANY; AUTHOR is a founder of COMPANY and a member of its scientific advisory board; This work was supported in part by a grant from COMPANY.
6. References must be numbered as they appear in the text. All authors must be listed for each reference. If citations are included in tables or in figure legends, they must be numbered according to the position of citation of the table or figure in the text. Only published papers and papers in press may be included in the References. In press articles, i.e., papers not yet published, must be submitted as online attachments in PDF format at the time of article submission. NOTE: Do NOT submit as attachment papers that are already published, e.g., manuscripts published ahead of print. Such papers must be incorporated into the References and cited with their DOI numbers and year of publication. Citations of "manuscripts in preparation," "unpublished observations," and "personal communications" must appear parenthetically in the text. Manuscripts "submitted for publication" (i.e., not yet accepted) also are mentioned parenthetically in the text. Written approval by the persons cited in personal communications must accompany the manuscript unless they are also authors of the manuscript submitted to Immune Network

• Format for references:

Periodicals: Wells, A. D., M. C. Walsh, D. Sankaran, and L. A. Turka. 2000. T cell
effector function and anergy avoidance are quantitatively linked to cell division. J.
Immunol. 165: 2432–2443.
Books: McIntyre, T. M., and W. Strober. 1999. Gut-associated lymphoid tissue:
regulation of IgA B-cell development. In Mucosal Immunology, 2nd ed. P. L. Ogra, J.
Mestecky, E. Lamm, W. Strober, J. Bienenstock, and J. R. McGhee, eds. Academic
Press, San Diego, CA. p. 319–356.
Articles published ahead of print: Fraser, D.A., A. K. Laust, E. L. Nelson, and A. J.
Tenner. 2009. C1q differentially modulates phagocytosis and cytokine responses during
ingestion of apoptotic cells by human monocytes, macrophages, and dendritic cells . J.
Immunol. doi:10.4049/jimmunol.0902232.

7. Abbreviations that may be used without definition are provided below. Spell out nonstandard abbreviations used less than three times. Nonstandard abbreviations used three or more times must be defined in a title page. Abbreviations and their definitions must be be consistent throughout the text.

The abbreviations listed below are used without definition in articles published in Immune Network. The form may be used for both singular and plural, or made plural with "s" at the author's option. The list of standard abbreviations is published in the first issue of each volume.

• Standard Abbreviations:

8. Tables must be numbered with Arabic numerals in order of appearance in the text. All tables must have a title. Table legends are prepared as footnotes to the table and are included with the table. Tables must be in DOC file format. Each table should be submitted as a separate file.
9. Figure legends must be numbered with Arabic numerals in order of appearance in the text and should include a short title after the figure number. Where possible, symbols and patterns used to distinguish data should be defined in a key placed within the graphic rather than in the figure legend. All figure legends must specify the number of times each experiment was independently performed, as well as the number of animals or replicates in each experimental group.

10. Figures: high-resolution figures that meet the following specifications must be submitted. For more information, see GUIDELINES and TIPS.

• Color: Color figures must be in the RGB color space.
• File Sizes: Figure files should not exceed 10 MB (average size is about 2 MB).
• Image Sizes: Figures should be submitted in final print publication size (printed 1:1).

Figures may be published in print in one of two formats: single-column (width from 3.37 to
8.23 cm) or double-column (width from 12.65 to 17.1 cm). The single-column format is
preferred. Unless the file size is too large, multi-panel figures should be submitted as a
single file.

• Text and Lines: Text in figures must be 6-8 points in size, except for single letter markers,

which may be 12 points. Helvetica or Arial should be used for all figure text (except for
the use of symbols). If Helvetica or Arial is not available to authors, Times Roman may be
used. Line widths must be greater than one point thick or they will not be visible on the  PDF version of the article.

• Numbering: Figures must be numbered as they appear in the text.
• File Format: Figures should be in TIFF (better for halftone art e.g., blots, photographs)

EPS (better for line art or monochrome art, i.e., anything that involves sharply delineated
lines), or PDF format. PowerPoint files are not suitable quality, as their resolution is too
low for print. Please click here for detailed instructions on converting PowerPoint files to
TIFF files.

• Cover Art: Cover art is selected from images in accepted articles and changes with each issue of Immune Network. Authors are encouraged to submit color figures with their manuscripts for possible use as cover illustrations. If an image is selected as cover art, the file must have a resolution of at least 300 dpi at a size of 8.5" x 11".

• Depositing In Public Databases
• High-resolution structural data: Any paper submitted to Immune Network that contains new high-resolution structural data requires an accession number from the Protein Data Bank and assurance that unrestricted release will occur at or before the time of publication. The accession number should be accompanied by the Website address of the databank.

• Nucleotide sequences: Sequences of nucleotides or amino acids longer than 50 bases/residues should not be presented in the text or in table form, but rather should be submitted as a publication-quality figure. Original nucleotide sequences, and determined nucleotide sequences encoding reported amino acid sequences, described in the manuscript must be submitted to GenBank or EMBL DataLibrary at the time of manuscript submission. An accession number and sequence availability are required at the time of publication. The accession number should be accompanied by the Website address of the databank.

• Microarray Data :Immune Network will not publish descriptive manuscripts that report microarray data, unless such information can be considered of unusual immunological significance and/or include functional experiments that provide novel insight into mechanism. As with other scientific approaches, current experimental, quantitation, verification, and statistical analyses are expected. Microarray experiments should be Minimum Information About a Microarray Experiment (MIAME) compliant.

Whereas limited online space may be available for supplemental tables associated with the manuscript, complete microarray data must be deposited in the appropriate public database (e.g., GEO, ArrayExpress, or CIBEX), and must be accessible without restriction from the date of publication. An entry name or accession number must be included in the paper before publication. The accession number should be accompanied by the Website address of the databank.

• Estimating Manuscript Length: One printed page in Immune Network contains approximately 8,000 characters, including spaces. Thus, an 8 page, Full-Length article would contain approximately 64,000 characters. Each line in a table occupies about 60 characters for a single-column table (120 characters for a double-column table). Figures occupy about 180 characters per centimeter height for single-column figures (360 characters for double-column figures). Determine the total character count for the text of your manuscript and add the character-equivalents for the tables and figures. This will provide a reasonable estimate for the printed length of a manuscript.

• Human And Animal Use: All studies involving human subjects must be conducted in accordance with the guidelines of the World Medical Association's Declaration of Helsinki (most recent revision). All animal studies must be performed in compliance with the U.S. Department of Health and Human Services Guide for the Care and Use of Laboratory Animals (or otherwise relevant guidelines). A statement that human and/or animal studies have been reviewed and approved by an appropriate institutional review committee must be included in the Materials and Methods section of the manuscript.

• Style Guide

General style conventions: In general, Immune Network follows Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers, seventh edition, published by the Council of Science Editors, Inc., in instances where style issues are not directlyaddressed.

Abbreviations for references:PubMed is the primary source for journal name abbreviations.

Nomenclature:

• Allergen nomenclature: Nomenclature for allergens should be assigned in cooperation with the IUIS Allergen Sub-Committee. Authors of accepted manuscripts that describe novel allergens will be requested to complete a brief standard form available at IUIS Allergen Nomenclature.
• CD nomenclature: For the purpose of consistency, Immune Network will follow CD nomenclature. For murine molecules, Immune Network will follow the nomenclature previously published (J. Immunol. 160: 3861-3868, 1998). For human molecules, standard CD nomenclature will be followed as updated (J. Immunol. 168: 2083-2086, 2002). See also HCDM
• Chemical names: Immune Network uses The Merck Index and the IUPAC-IUB Commission on Biochemical Nomenclature-Chemical Abstracts as the primary references for proper spelling and style of chemical names.
• Chemokine/chemokine receptor nomenclature: The systematic name for chemokines and chemokine receptors should be used. The original name may be given in parenthesis if desired. See Cytokine 21:48-9, 2003.
• Enzyme Nomenclature is Immune Network source for style and spelling of enzyme names.
• Gene nomenclature: The HUGO guidelines for gene nomenclature may be used for naming human genes. Mouse Genome Informatics is a reference source for naming mouse genes.
• Genetic nomenclature for mice :Immune Network uses the revisions for standardized genetic nomenclature for mice published periodically in Mouse Genome. A current listing of inbred strains of mice and rats is available at Mouse Genome Informatics. Authors are encouraged to deposit their mapping data with the Mouse Genome Database (MGD) before publication and to include the assigned MGD accession numbers in their manuscripts. Data may be submitted electronically by e-mail. Information about electronic submission of datasets can be obtained at the Data and Nomenclature Submissions page. Gene symbols should be reserved with MGD in advance of publication. An electronic nomenclature submission form is available from the MGD Web site.
• HLA nomenclature: HLA nomenclature is updated periodically by the WHO Nomenclature Committee for Factors of the HLA System. A recent reference is Hum. Immunol. 64: 919-20, 2003. Annual comprehensive revisions are published in Human Immunology, usually in the spring. See also: EMBL-EBI

• Supplemental Materials

• Supplemental Data:

Supporting data that are not essential to understanding the material presented in the manuscript may be submitted with the original paper for peer review; however, the print version of the paper must stand on its own without the Supplemental Data.
Supplemental material is primarily intended for short videos or large tables, large sequence alignments, or large data sets. Additional supplemental figures and tables that support the interpretation and conclusions drawn in the manuscript may, however, also be submitted for review with the manuscript.
Supplemental Data must be submitted as separate files from the rest of the manuscript during the online submission; select "Supplemental Data" as the "File Type" when uploading the files.
For Brief report manuscripts, no more than two supplemental figures and/or tables may be submitted; for Full-Length manuscripts, no more than four supplemental figures and/or tables may be submitted.
Legends or short explanations must accompany all supplemental figures; no other supplementary text is permitted.

• Videos must be 320 x 480 pixels or smaller for best viewing within a browser. Videos must be no longer than 30 seconds and under 10 MB, with no sound or voice-over. Submit videos in MPG or QuickTime format. Change QuickTime file extensions to ".mov" so that Web browsers will recognize the file type and play the movie. Compress videos as much as possible to help control file size. Name videos by order of citation appearance (e.g., video1.mov). Select "Video" as the "File Type" when uploading the files during online submission. Authors will be notified if problems exist with videos as submitted and will be asked to take responsibility for modifications. No editing will be done to videos at the Editorial Office.

Links to the Supplemental Material will appear in two places in the online journal: in the Table of Contents and in the information box associated with the first page of the full-text article. There will not be any links in the body of the article. In the printed paper, supplemental material will be footnoted the first time mentioned: "The online version of this article contains supplemental
material."

Brief Report Manuscripts
Manuscripts submitted to the brief report section should conform to the General Guidelines for Full-Length manuscripts as well as the additional guidelines below:

1. Brief report, including figures and references, must fit within 4 journal pages. See Estimating Manuscript Length for how to estimate the size of figures and tables and limit the text accordingly. One printed page in Immune Network contains approximately 8,000 characters, including spaces. Thus, a 4-page Cutting Edge article would contain approximately 32,000 characters.
2. The Abstract is limited to 150 words.
3. The Materials and Methods section may be sharply limited but should be sufficient to allow the evaluation of results and conclusions.
4. Authors may combine the Results and Discussion sections.

Reviews
Immne Network publishes full-length reviews on topics of interest to its broad readership. Abstract contains less than 250 words. Reviews are usually approximately 5000 words in length with less than 100 references and two to three figures. 
Minireviews
Minireviews discuss a sharply focused scientific topic of interest, usually highlighting emerging themes from papers in the recent literature. Abstract contains less than 250 words. Minireviews must fit within four pages of the journal and therefore can be no more than 3500 words in length (including figure legends, a 40-word abstract, and no more than 20 references) and may include one or two figures.

Technical and Case reports
A Technical and Case Report presents primary research data on new technique and clinical cases that are likely to be influential. This format is not a review of technology and clinical immunology, but its primary report in the literature. It may involve a biological discovery to prove the usefulness of the technique and clinical case, but this is not a requirement. Both Technical and Case Reports have a format broadly similar to that of full-length manuscripts, though many Technical and Case Reports are shorter than a typical Article. They begin with an unreferenced abstract (typically less than 250 words) followed by separate sections for introduction, Results, Discussion (with optional subheadings) and Methods. If statistical testing was used to analyze the data, the Methods section must contain a subsection on statistical analysis. There is no strict limit on the number of display items. References are normally limited to 30, but this can be flexible at the editor’s discretion. Technical and Case Reports include received/accepted dates. They may be accompanied by supplementary information. Technical and Case Reports are peer reviewed, and authors must provide a competing financial interests statement before publication.

Preparation of The Revised Manuscript
Submit online at submit.immuenetwork.org. Follow Immune Network Editorial Office instructions contained in the previous decision letter carefully and thoroughly. A revised manuscript not returned within nine months of the date of the decision letter will be considered a new manuscript and subject to a new, complete review.

Individual manuscript files, files for each figure and table (even if they are unchanged from the previous submission), and a point-by-point reply to all referee comments, must be uploaded to the system. The revised manuscript text must be marked to show changes using yellow highlighting (Microsoft Word files preferred). Do not show deletions, because if the manuscript is accepted, this version will be immediately sent for publication. High-resolution figure files must be submitted. Figures must be in TIFF or EPS format and prepared as described under Figures. Authors should retain for themselves copies of all the files in their original formats.

After the manuscript has been checked by journal staff, the Corresponding Author will receive an email acknowledging receipt of the revised manuscript. Please contact journal@immunenetwork.org if you do not receive the acknowledgment email.

-----------------------------------------------------------------------------------------------------------
Submit Online

• Cover Letter

Each submission should be accompanied by a cover letter that addresses three questions: (1) what is the scientific question being asked by this study, (2) what are the principal new findings that answer this question, and (3) what is the significance of the results for the field? The authors' answers to these questions will not only help the editors in selecting appropriate reviewers, but will be forwarded to the referees along with the manuscript to aid in the review process. A cover letter may contain suggestions for appropriate reviewers and up to three requests for reviewer exclusions. The cover letter is confidential to the editor and will not be seen by reviewers.

Submit online at submit.immunenetwork.org. For the initial submission of Full-Length manuscripts and Brief report manuscript, individual manuscript, figure, and table files may be uploaded to the system. The system then creates a single PDF for review purposes. Authors should save copies for themselves of all the files in their original formats. See Author Instructions for online submission requirements. See the Figures section for help with preparing digital art. Immune Network online submission system requires browsers where cookies and Javascript are enabled.

The system will ask submitters to designate the corresponding author. This corresponding author is the person who signs the submission form and the publication charges form, and who receives and responds to communication from the editors and Editorial Office during the peer-review process. It does not refer to the person with whom readers may correspond after an article is published. The corresponding author designation in the online system cannot be changed after a paper has been accepted.

After the manuscript has been checked by journal staff, the Corresponding Author will receive an email acknowledging receipt of the manuscript. Please contact journal@immunenetwork.org if you do not receive the acknowledgment e-mail.
-------------------------------------------------------------------------------------------------
Reprints
Reprints must be ordered in advance of publication. A Reprint Form showing the cost of reprints, together with an order slip, is sent with the electronic page proofs. The invoice for reprints will also include page charges and color figure charges. Reprint orders from noncontributors must be directed to the Editorial Office.

Peer Review Information

• The Process
• Decisions
• Communication with Authors
• Manuscripts Submitted from the Institution of an Editor
•  Rebuttals

The Process: By submitting a manuscript to Immune Network , the authors agree to subject it to the confidential peer-review process.
Editors and reviewers are informed that the manuscript must be considered confidential. After a manuscript is received, it is assigned by scientists on staff to a specific Deputy Editor and a Section Editor, whose expertise is considered to be appropriate. The Section Editor prepares a list of expert reviewers, which may include some suggested by the scientists.
Authors can indicate specific individuals whom they would like to have excluded as reviewers. Generally, requests to exclude certain potential reviewers will be honored except in fields with a limited number of experts.

All potential reviewers are contacted individually to determine availability. Manuscript files are sent to at least two expert reviewers. Reviewers are asked to complete the review of the manuscript within two weeks and to return a short review form.
Based on the reviewers' comments, the Section Editor recommends a course of action and communicates the reviews and recommendations to the Deputy Editor for a final decision.

The Deputy Editor considers the comments made by the reviewers and the recommendation of the Section Editor, selects those comments to be shared with the authors, makes a final decision concerning the manuscript, and prepares the decision letter for signature by the Editor-in-Chief. If revisions of the manuscript are suggested, the Deputy Editor also recommends who should review the revised paper when resubmitted. Authors are informed of the decision by e-mail; appropriate comments from reviewers and editors are appended.

Decisions: There are four categories for initial decisions: accept, accept with minor revision, return for revision, and reject.
Some manuscripts are accepted provisionally, pending relatively minor revisions. In this case, the Deputy Editor may conduct the rereview. For many manuscripts, authors are invited to resubmit if revision or additional experimentation can address major criticisms. Typically, one or more reviewers will then be asked to consider the adequacy of the revisions. All revised manuscripts are carefully reexamined, and ultimate acceptability is not guaranteed. Immune Network does not provide for an advance determination of the acceptability of a particular manuscript for publication, nor does it promise expedited review of selected manuscripts.

Communication With Authors: To minimize the possibility of misinterpretation or errors in verbal communication, the Editorial Office will provide information, in writing, only to the corresponding author and will not provide extensive details (e.g., exact status of a review or a predicted time to final decision). Deputy Editors do not take calls from authors concerning decisions or other related matters. All such inquiries should be addressed in writing to the Editor-in-Chief, who will discuss concerns with the Deputy Editor. This policy has been established to provide for uniformity and fairness in addressing concerns about the review process.

Manuscripts Submitted From The Institution Of An Editor: Manuscripts submitted from the institution of any Section or Deputy Editor or the Editor-in-Chief are reviewed by other editors from outside that institution. The Editorial Office ensures confidentiality and equity in reviewing all manuscripts.

Rebuttals: If the authors believe that a serious scientific error occurred during the review, a letter of rebuttal may be sent to the Editor-in-Chief, explaining the reasons why the decision should be reconsidered. Letters of rebuttal must be received by the Editor-in-Chief within six weeks of the date the decision letter was sent. When appropriate, the matter will be taken up with the initial Deputy Editor, Section Editor, or additional reviewers. Rebuttals that challenge rejections that were based on priority alone are rarely successful, since the assignment of priority is necessarily a matter of opinion. If the authors of a rejected manuscript are able to make new advances that go far beyond the original submission, they will often expedite consideration of their paper through the submission of a completely new manuscript.

Reviewers

Selection: Selection of reviewers is the responsibility of the Section Editor, although the scientists on staff make recommendations to the Section Editor from a database of individuals who have reviewed manuscripts previously. This database includes self-identified areas of expertise as well as information about the perceived usefulness and timeliness of past reviews. Individuals who consistently have provided tardy or unhelpful reviews are removed from the database. Every effort is made to avoid both real and apparent conflicts of interest with respect to research activities or collaborative or personal interactions. Reviewers are asked to withdraw from considering any manuscript in which they identify a conflict that has escaped the attention of the Section Editor.

Scientific Integrity: Information contained in manuscripts is considered confidential and should not be shared or distributed. If necessary, a reviewer can consult with others for an adequate evaluation of the research findings if all individuals involved maintain confidentiality, objectivity, and avoid conflict of interest. KAI is not responsible for acts and conduct by reviewers that are not in accordance with accepted professional standards. Reviewers are asked to be objective in their evaluations and to judge primarily the novelty and soundness of the information presented.

Anonymity: Although reviews are anonymous, all comments should be capable of withstanding public scrutiny. Except in very unusual circumstances, the identity of the reviewers and Section and Deputy Editors involved in the review of any given manuscript is kept confidential.

Immune Network Editorial Board

The KAI Council, upon recommendation of the Publications Committee, appoints the Editor-in-Chief for a term of two years.
Deputy Editors, Section Editors, and Associate Editors are nominated by the Editor-in-Chief and appointed by the Publications Committee. The Editor-in-Chief, the Deputy Editors, and the Section Editors constitute the Editorial Board. Deputy Editors are appointed for variable terms. Section Editors and Associate Editors are appointed for one renewable term of two years in most circumstances. Deputy Editors, Section Editors, and Associate Editors are required to be members of KAI. The Editor-in-Chief is responsible for the specific editorial conduct of Immune Network. The KAI Publications Committee is responsible for the management and evaluation of Immune Network and any other official publications of KAI, subject to the general supervision of the KAI Council.

Contact Information
Immune Network